secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001701541-21-000038
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q3 2021 cash $235M; BDTX-189 Phase 2 on track for year-end
--------------------------------------------------------------------------------

- Cash, equivalents, and investments $235.0M as of Sept 30, 2021; expected runway into H2 2023.
- Net cash used in operations Q3 2021 was $26.5M, up from $11.5M in Q3 2020.
- R&D expenses $27.6M (Q3 2021) vs $12.9M (Q3 2020), driven by headcount and preclinical/clinical costs.
- BDTX-189 Phase 2 portion initiation by end of 2021; BDTX-1535 IND filing targeted H1 2022.
- Preclinical data for BDTX-1535, BRAF, and FGFR programs presented at ANE conference; partnership with OpenEye Scientific.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154121000038/0001701541-21-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154121000038/bdtx-20211108.htm
  HTML page:      https://secwatch.observer/filing/0001701541-21-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer